<p>2024 年 11 月 12 日- 上午 09:25</p>
<p><em>耳科學與神經耳科學研究概述了突破性全植入式人工耳蝸的早期經驗和潛在好處</em></p>
<p><em>明尼蘇達州白熊湖，2024 年 11 月 12 日（全球新聞稿）--</em> Envoy Medical®, Inc.（“Envoy Medical”）（納斯達克：“COCH”），一家專注於全植入式聽力系統的聽力健康公司，今天宣佈在_耳科學與神經耳科學_上發表了一篇經過同行評審的論文，討論了與公司正在研究的全植入式 Acclaim <strong>®</strong> 人工耳蝸（Acclaim CI）的早期經驗，並強調其潛在好處。該論文標題為 “新型全植入式人工耳蝸的早期聽力結果和聽力學經驗”，討論了一項首次在人類中進行的早期可行性研究的初步結果。該研究在收集和分析這些數據時僅進行了六個月。所有三名患者目前都已植入近兩年。</p>
<p>“這篇出版物開始指出全植入式人工耳蝸的潛在現實世界好處。聽力損失伴隨你一整天——你無法摘掉或關閉你的聽力損失——因此，能夠在一天中隨時接觸聲音的全植入式聽力解決方案的潛在好處讓許多患者感到興奮。我們對參與研究這一突破性設備的三名患者表示感謝。我們學到了很多，並期待將這些經驗應用於我們最近獲得 FDA 批准開始的關鍵臨牀試驗中的更大患者羣體，” Envoy Medical 首席執行官 Brent Lucas 説道。</p>
<p>主要亮點包括：</p>
<ul>
<li>所有接受者都是其設備的常規用户。一名患者報告稱其設備持續使用（晝夜不息），研究作者認為這可能支持改善言語和生活質量的結果。</li>
<li>三名患者中有兩名報告稱通過在與人工耳蝸相同的耳朵中使用助聽器來優化其聽力收益。這種靈活性和選擇性可能對潛在用户帶來現實生活中的好處。Acclaim CI 設計為利用耳朵捕捉聲音，這為助聽器、耳塞或其他消費電子設備在植入耳中使用提供了機會。</li>
<li>所有患者報告在一次充電後使用時間在三到五天之間。</li>
<li>作者指出該設備可以在夜間使用，這可能為患者提供了一種安全感，而這種安全感是部分植入設備在夜間移除外部組件時無法提供的。</li>
</ul>
<p><strong>關於全植入式 Acclaim®人工耳蝸</strong></p>
<p>我們相信全植入式 Acclaim 人工耳蝸（“Acclaim CI”）是首個此類聽力設備。Envoy Medical 的全植入式技術包括一個傳感器，旨在利用耳朵的自然解剖結構，而不是麥克風來捕捉聲音。</p>
<p>Acclaim CI 旨在解決嚴重到極重度的感音神經性聽力損失，而這種損失無法通過助聽器得到充分解決。Acclaim CI 預計將適用於被合格醫生評估為合適候選人的成年人。</p>
<p>Acclaim 人工耳蝸於 2019 年獲得美國食品和藥物管理局（FDA）的突破性設備認證。</p>
<p><strong>警告 全植入式 Acclaim 人工耳蝸是一種研究性設備。根據聯邦（或美國）法律，僅限於研究使用。</strong></p>
<p><strong>關於 Esteem®全植入式主動中耳植入物（FI-AMEI）</strong></p>
<p>Esteem 全植入式主動中耳植入物（FI-AMEI）是唯一獲得 FDA 批准的全植入式 * 聽力設備，適用於被診斷為中度至重度感音神經性聽力損失的成年人，允許使用耳朵的自然解剖結構實現 24/7 的聽力能力。Esteem FI-AMEI 聽力植入物是隱形的，不需要外部佩戴的組件，也不需要在耳道中放置任何東西以使其正常工作。與助聽器不同，你永遠不需要佩戴或摘下它。你無法丟失它。你不需要清潔它。Esteem FI-AMEI 聽力植入物提供真正的 24/7 聽力。</p>
<p>* 一旦激活，外部 Esteem FI-AMEI 個人編程器在日常使用中不再需要。</p>
<p>有關 Esteem FI-AMEI 的重要安全信息，請訪問：https://www.envoymedical.com/safety-information。</p>
<p><strong>附加信息及獲取途徑</strong></p>
<p>Envoy Medical 向 SEC 提交的文件副本可在 SEC 網站 www.sec.gov 免費獲取。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1995 年美國私人證券訴訟改革法案的 “安全港” 條款定義的 “前瞻性聲明”。前瞻性聲明可以通過使用諸如 “估計”、“計劃”、“項目”、“預測”、“打算”、“將”、“期望”、“預期”、“相信”、“尋求”、“目標” 或其他類似表達來識別，這些詞預測或指示未來事件或趨勢，或者不是歷史事項的陳述，但缺乏這些詞並不意味着該聲明不是前瞻性的。這些聲明可能包括但不限於關於 Envoy Medical 對其業務前景、生產力、未來運營改進和資本投資計劃及目標的期望；Acclaim CI 作為市場上首個完全植入的人工耳蝸；Acclaim CI 的安全性、性能和市場接受度；以及關於 Envoy Medical 可能或假定的未來運營的任何信息。本新聞稿中包含的前瞻性聲明反映了 Envoy Medical 對未來事件的當前看法，並受到眾多已知和未知風險、不確定性、假設和情況變化的影響，這些因素可能導致其實際結果與任何前瞻性聲明中表達的結果顯著不同。Envoy Medical 不保證所描述的事件會如所述發生（或會發生）。這些前瞻性聲明面臨許多風險和不確定性，包括但不限於 Envoy Medical A 類普通股的市場價格變化；Envoy Medical 股票在任何指數中的納入變化或移除；Envoy Medical 在保留或招聘其高管、關鍵員工或董事方面的成功，或所需的變更；醫療器械行業的不可預測性、批准醫療器械的監管過程以及 Envoy Medical 產品的臨牀開發過程；醫療器械行業的競爭，以及未能及時以具有競爭力的價格推出新產品和服務以成功與競爭對手競爭；與 Envoy Medical 供應商的關係中斷，或 Envoy Medical 自身在其產品的一些關鍵組件和材料的生產能力中斷；資本需求的變化及融資和資本的可用性變化；利率或通貨膨脹率的變化；法律、監管和其他訴訟可能會耗費高昂的成本和時間進行辯護；適用法律或法規的變化，或其在 Envoy Medical 上的適用；Envoy Medical 任何關鍵知識產權的喪失或未能充分保護知識產權；災難性事件的影響，包括戰爭、恐怖主義和其他國際衝突；以及 Envoy Medical 在 2024 年 4 月 1 日提交的 10-K 表格年報中 “風險因素” 和 “關於前瞻性聲明的警示説明” 部分中列出的其他風險和不確定性。如果這些風險中的任何一個實現，或 Envoy Medical 的假設被證明不正確，實際結果可能與這些前瞻性聲明所暗示的結果有重大差異。雖然前瞻性聲明反映了 Envoy Medical 的善意信念，但它們並不是未來表現的保證。Envoy Medical 不承擔任何公開更新或修訂任何前瞻性聲明的義務，以反映基礎假設或因素、新信息、數據或方法、未來事件或本新聞稿日期後的其他變化，除非適用法律要求。您不應對任何前瞻性聲明過度依賴，這些聲明僅基於 Envoy Medical 當前可用的信息。</p>
<h3></h3>
<p><strong>投資者聯繫：</strong></p>
<p>CORE IR</p>
<p>516-222-2560</p>
<p>investorrelations@envoymedical.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RJM01UVXhPU00yTlRjMk5qYzJJelV3TURFeE9UVXlPQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RJM01UVXhPU00yTlRjMk5qYzJJelV3TURFeE9UVXlPQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzBmOGE3OGQtNDBmOC00OWY0LWE1MWQtMTc5NGFlMGI4Y2JhLTUwMDExOTUyOA==/tiny/Envoy-Medical-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzBmOGE3OGQtNDBmOC00OWY0LWE1MWQtMTc5NGFlMGI4Y2JhLTUwMDExOTUyOA==/tiny/Envoy-Medical-Inc.png"/></p>

COCH

<p>Envoy Medical, Inc.（納斯達克代碼：COCH）宣佈在《耳科學與神經耳科學》期刊上發表了一篇經過同行評審的文章，詳細介紹了其全植入式 Acclaim®人工耳蝸的早期經驗。研究強調了潛在的好處，包括患者的持續使用和生活質量的改善。Acclaim CI 旨在用於重度至極重度感音神經性聽力損失，利用耳朵的自然解剖結構進行聲音捕捉。該設備於 2019 年獲得 FDA 突破性醫療器械認證，目前仍處於研究階段。首席執行官 Brent Lucas 對參與者表示感謝，並對未來的試驗充滿樂觀</p>

<p>11/12/2024 - 09:25 AM</p>
<div class="lb-trans"><p>2024 年 11 月 12 日- 上午 09:25</p>
</div><p><em>Study in Otology &amp; Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant</em></p>
<div class="lb-trans"><p><em>耳科學與神經耳科學研究概述了突破性全植入式人工耳蝸的早期經驗和潛在好處</em></p>
</div><p><em>WHITE BEAR LAKE, Minnesota , Nov. 12, 2024 (GLOBE NEWSWIRE) --</em> Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces a peer-reviewed publication in <em>Otology &amp; Neurotology</em>, discussing early experiences with and highlighting potential benefits of the Company’s investigational fully implanted Acclaim <strong>®</strong> Cochlear Implant (Acclaim CI). The paper, titled, “Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant,” discusses the initial results from a first-in-human, early feasibility study. The study had only been active for six months at the time these data being reported were collected and analyzed. All three patients are now approaching two years with their implants.</p>
<div class="lb-trans"><p><em>明尼蘇達州白熊湖，2024 年 11 月 12 日（全球新聞稿）--</em> Envoy Medical®, Inc.（“Envoy Medical”）（納斯達克：“COCH”），一家專注於全植入式聽力系統的聽力健康公司，今天宣佈在_耳科學與神經耳科學_上發表了一篇經過同行評審的論文，討論了與公司正在研究的全植入式 Acclaim <strong>®</strong> 人工耳蝸（Acclaim CI）的早期經驗，並強調其潛在好處。該論文標題為 “新型全植入式人工耳蝸的早期聽力結果和聽力學經驗”，討論了一項首次在人類中進行的早期可行性研究的初步結果。該研究在收集和分析這些數據時僅進行了六個月。所有三名患者目前都已植入近兩年。</p>
</div><p>“This publication begins to point out potential real-world benefits of a fully implanted cochlear implant. Hearing loss is with you all day – you cannot take off or shut off your hearing loss – so the potential benefit of a fully implanted hearing solution that allows access to sound throughout the day is exciting to think about for many patients. We are grateful for the three patients who participated to help us study this breakthrough device. We have learned a great deal and look forward to applying those learnings to a larger group of patients in our pivotal clinical trial, which we recently received FDA’s approval to begin,” said Brent Lucas, Envoy Medical CEO.</p>
<div class="lb-trans"><p>“這篇出版物開始指出全植入式人工耳蝸的潛在現實世界好處。聽力損失伴隨你一整天——你無法摘掉或關閉你的聽力損失——因此，能夠在一天中隨時接觸聲音的全植入式聽力解決方案的潛在好處讓許多患者感到興奮。我們對參與研究這一突破性設備的三名患者表示感謝。我們學到了很多，並期待將這些經驗應用於我們最近獲得 FDA 批准開始的關鍵臨牀試驗中的更大患者羣體，” Envoy Medical 首席執行官 Brent Lucas 説道。</p>
</div><p>Key highlights included:</p>
<div class="lb-trans"><p>主要亮點包括：</p>
</div><ul>
<li>All recipients were regular users of their devices. One patient reported using their device continuously (day and night), which study authors believe may support improved speech and quality of life outcomes.</li>
<li>Two of the three patients report optimizing their hearing benefit by using a hearing aid in the same ear as the cochlear implant. This flexibility and optionality could be a real-life benefit to potential users. Acclaim CI is designed to use the ear to pick up sound, which enables an opportunity for devices such as hearing aids, earbuds, or other consumer electronics to be used in the implanted ear.</li>
<li>All reported between three and five days of use on one charge.</li>
<li>Authors noted the ability of the device to be used at night, which may offer patients a sense of security that they cannot have with partially implanted devices where the externals are removed at night.</li>
</ul>
<div class="lb-trans"><ul>
<li>所有接受者都是其設備的常規用户。一名患者報告稱其設備持續使用（晝夜不息），研究作者認為這可能支持改善言語和生活質量的結果。</li>
<li>三名患者中有兩名報告稱通過在與人工耳蝸相同的耳朵中使用助聽器來優化其聽力收益。這種靈活性和選擇性可能對潛在用户帶來現實生活中的好處。Acclaim CI 設計為利用耳朵捕捉聲音，這為助聽器、耳塞或其他消費電子設備在植入耳中使用提供了機會。</li>
<li>所有患者報告在一次充電後使用時間在三到五天之間。</li>
<li>作者指出該設備可以在夜間使用，這可能為患者提供了一種安全感，而這種安全感是部分植入設備在夜間移除外部組件時無法提供的。</li>
</ul>
</div><p><strong>About the Fully Implanted Acclaim® Cochlear Implant</strong></p>
<div class="lb-trans"><p><strong>關於全植入式 Acclaim®人工耳蝸</strong></p>
</div><p>We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.</p>
<div class="lb-trans"><p>我們相信全植入式 Acclaim 人工耳蝸（“Acclaim CI”）是首個此類聽力設備。Envoy Medical 的全植入式技術包括一個傳感器，旨在利用耳朵的自然解剖結構，而不是麥克風來捕捉聲音。</p>
</div><p>The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.</p>
<div class="lb-trans"><p>Acclaim CI 旨在解決嚴重到極重度的感音神經性聽力損失，而這種損失無法通過助聽器得到充分解決。Acclaim CI 預計將適用於被合格醫生評估為合適候選人的成年人。</p>
</div><p>The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.</p>
<div class="lb-trans"><p>Acclaim 人工耳蝸於 2019 年獲得美國食品和藥物管理局（FDA）的突破性設備認證。</p>
</div><p><strong>CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.</strong></p>
<div class="lb-trans"><p><strong>警告 全植入式 Acclaim 人工耳蝸是一種研究性設備。根據聯邦（或美國）法律，僅限於研究使用。</strong></p>
</div><p><strong>About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)</strong></p>
<div class="lb-trans"><p><strong>關於 Esteem®全植入式主動中耳植入物（FI-AMEI）</strong></p>
</div><p>The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.</p>
<div class="lb-trans"><p>Esteem 全植入式主動中耳植入物（FI-AMEI）是唯一獲得 FDA 批准的全植入式 * 聽力設備，適用於被診斷為中度至重度感音神經性聽力損失的成年人，允許使用耳朵的自然解剖結構實現 24/7 的聽力能力。Esteem FI-AMEI 聽力植入物是隱形的，不需要外部佩戴的組件，也不需要在耳道中放置任何東西以使其正常工作。與助聽器不同，你永遠不需要佩戴或摘下它。你無法丟失它。你不需要清潔它。Esteem FI-AMEI 聽力植入物提供真正的 24/7 聽力。</p>
</div><p>*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.</p>
<div class="lb-trans"><p>* 一旦激活，外部 Esteem FI-AMEI 個人編程器在日常使用中不再需要。</p>
</div><p>Important safety information for the Esteem FI-AMEI can be found at:https://www.envoymedical.com/safety-information.</p>
<div class="lb-trans"><p>有關 Esteem FI-AMEI 的重要安全信息，請訪問：https://www.envoymedical.com/safety-information。</p>
</div><p><strong>Additional Information and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>附加信息及獲取途徑</strong></p>
</div><p>Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website atwww.sec.gov.</p>
<div class="lb-trans"><p>Envoy Medical 向 SEC 提交的文件副本可在 SEC 網站 www.sec.gov 免費獲取。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1995 年美國私人證券訴訟改革法案的 “安全港” 條款定義的 “前瞻性聲明”。前瞻性聲明可以通過使用諸如 “估計”、“計劃”、“項目”、“預測”、“打算”、“將”、“期望”、“預期”、“相信”、“尋求”、“目標” 或其他類似表達來識別，這些詞預測或指示未來事件或趨勢，或者不是歷史事項的陳述，但缺乏這些詞並不意味着該聲明不是前瞻性的。這些聲明可能包括但不限於關於 Envoy Medical 對其業務前景、生產力、未來運營改進和資本投資計劃及目標的期望；Acclaim CI 作為市場上首個完全植入的人工耳蝸；Acclaim CI 的安全性、性能和市場接受度；以及關於 Envoy Medical 可能或假定的未來運營的任何信息。本新聞稿中包含的前瞻性聲明反映了 Envoy Medical 對未來事件的當前看法，並受到眾多已知和未知風險、不確定性、假設和情況變化的影響，這些因素可能導致其實際結果與任何前瞻性聲明中表達的結果顯著不同。Envoy Medical 不保證所描述的事件會如所述發生（或會發生）。這些前瞻性聲明面臨許多風險和不確定性，包括但不限於 Envoy Medical A 類普通股的市場價格變化；Envoy Medical 股票在任何指數中的納入變化或移除；Envoy Medical 在保留或招聘其高管、關鍵員工或董事方面的成功，或所需的變更；醫療器械行業的不可預測性、批准醫療器械的監管過程以及 Envoy Medical 產品的臨牀開發過程；醫療器械行業的競爭，以及未能及時以具有競爭力的價格推出新產品和服務以成功與競爭對手競爭；與 Envoy Medical 供應商的關係中斷，或 Envoy Medical 自身在其產品的一些關鍵組件和材料的生產能力中斷；資本需求的變化及融資和資本的可用性變化；利率或通貨膨脹率的變化；法律、監管和其他訴訟可能會耗費高昂的成本和時間進行辯護；適用法律或法規的變化，或其在 Envoy Medical 上的適用；Envoy Medical 任何關鍵知識產權的喪失或未能充分保護知識產權；災難性事件的影響，包括戰爭、恐怖主義和其他國際衝突；以及 Envoy Medical 在 2024 年 4 月 1 日提交的 10-K 表格年報中 “風險因素” 和 “關於前瞻性聲明的警示説明” 部分中列出的其他風險和不確定性。如果這些風險中的任何一個實現，或 Envoy Medical 的假設被證明不正確，實際結果可能與這些前瞻性聲明所暗示的結果有重大差異。雖然前瞻性聲明反映了 Envoy Medical 的善意信念，但它們並不是未來表現的保證。Envoy Medical 不承擔任何公開更新或修訂任何前瞻性聲明的義務，以反映基礎假設或因素、新信息、數據或方法、未來事件或本新聞稿日期後的其他變化，除非適用法律要求。您不應對任何前瞻性聲明過度依賴，這些聲明僅基於 Envoy Medical 當前可用的信息。</p>
</div><h3></h3>
<div class="lb-trans"><h3></h3>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p>CORE IR</p>
<div class="lb-trans"><p>CORE IR</p>
</div><p>516-222-2560</p>
<div class="lb-trans"><p>516-222-2560</p>
</div><p>investorrelations@envoymedical.com</p>
<div class="lb-trans"><p>investorrelations@envoymedical.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RJM01UVXhPU00yTlRjMk5qYzJJelV3TURFeE9UVXlPQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTI3MTUxOSM2NTc2Njc2IzUwMDExOTUyOA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzBmOGE3OGQtNDBmOC00OWY0LWE1MWQtMTc5NGFlMGI4Y2JhLTUwMDExOTUyOA==/tiny/Envoy-Medical-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/YzBmOGE3OGQtNDBmOC00OWY0LWE1MWQtMTc5NGFlMGI4Y2JhLTUwMDExOTUyOA==/tiny/Envoy-Medical-Inc.png"/></p>

Envoy Medical 的完全植入式 Acclaim®人工耳蝸在同行評審的出版物中被重點介紹 | COCH 股票新聞